Company

DeepWise

深度智控

DeepWise (深睿医疗) is a medical AI company that has evolved from a pure imaging-AI player into a full-stack healthcare AI enterprise. Founded no later than 2018 — when it already had products in market — it acquired 依图医疗 (Yitu Healthcare) in 2021 to add a "text + imaging" dual-AI engine, expanding beyond radiology into multi-modal medical data governance and research .

Its flagship platform, Deepwise MetAI, integrates the entire clinical workflow — from image reconstruction and assisted diagnosis to structured report generation and multi-modal data research — rather than offering point solutions for single findings . A separate platform, Deepwise TrioData, focuses on hospital-wide multi-modal big data fusion and governance . The company holds 14 NMPA Class III certificates, including a milestone 2024 approval for China's first lung cancer AI diagnostic product .

DeepWise targets multiple settings: tertiary hospitals,体检 (health checkup) centers with products like "睿心宝" and "睿肺宝," and基层 (grassroots) institutions through regional cloud-imaging centers for medical consortia . Despite the medical AI sector's broader struggles with monetization, DeepWise has reportedly achieved stable cash flow and leading market share through a multi-scene, multi-channel sales model .

The company is backed by Dalton Venture (道彤投资), which published a detailed portfolio profile in early 2025 . Note: elsewhere's corpus does not cover DeepWise's founding year, exact funding history, or valuation.

AI-generated — may contain errors, please verify.

DeepWiseCompany
深度智控
渲染中…
Mentioned in 13 articles

Coverage